MariaDB uses SPAC to begin NYSE trading in a tough market for public offerings
MariaDB has celebrated going public a few weeks before the end of a year which has seen a dramatic shift in the fortunes of tech companies raising money on the world's stock exchanges.announced
The investment comes on the back of a difficult year for those hoping to raise cash by going public. Global consultancy EY just released its quarterly IPO data report showing in 2022 the number of US tech IPOs dropped 85 percent – from 128 to 19 – while their total valuation dropped 97 percent – from $69.4 billion to $1.6 billion compared to 2021.it was hard to see many database companies using stock exchanges as a funding model in the immediate future.
Angel Pond was started by CEO and chairman Ted Wang, the founder of Puissance Capital Management and a former partner at Goldman Sachs, and Simon Xie, co-founder of Alibaba Group. "For IPO in and of itself, it gave us an efficient and knowledgeable means to go public. Without having these people surrounding you, you're kind of a babe in the woods," Howard said.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Real-life Lassie saved neighbour's life when he got trapped down a (foot) wellGreat-grandfather Morris Cohen developed hypothermia and needed to spend ten days in hospital, but he survived thanks to jackapoo Roger.
Consulte Mais informação »
Population, Clinical, and Scientific Impact of National Cancer Institute's National Clinical Trials Network Treatment Studies | Journal of Clinical OncologyPURPOSE In the United States, the National Cancer Institute National Cancer Clinical Trials Network (NCTN) groups have conducted publicly funded oncology research for 50 years. The combined impact of all adult network group trials has never been systematically examined. METHODS We identified randomized, phase III trials from the adult NCTN groups, reported from 1980 onward, with statistically significant findings for ≥ 1 clinical, time-dependent outcomes. In the subset of trials in which the experimental arm improved overall survival, gains in population life-years were estimated by deriving trial-specific hazard functions and hazard ratios to estimate the experimental treatment benefit and then mapping this trial-level benefit onto the US cancer population using registry and life-table data. Scientific impact was based on citation data from Google Scholar. Federal investment costs per life-year gained were estimated. The results were derived through December 31, 2020. RESULTS One hundred sixty-two trials comprised of 108,334 patients were analyzed, representing 29.8% (162/544) of trials conducted. The most common cancers included breast (34), gynecologic (28), and lung (14). The trials were cited 165,336 times (mean, 62.2 citations/trial/year); 87.7% of trials were cited in cancer care guidelines in favor of the recommended treatment. These studies were estimated to have generated 14.2 million (95% CI, 11.5 to 16.5 million) additional life-years to patients with cancer, with projected gains of 24.1 million (95% CI, 19.7 to 28.2 million) life-years by 2030. The federal investment cost per life-year gained through 2020 was $326 in US dollars. CONCLUSION NCTN randomized trials have been widely cited and are routinely included in clinical guidelines. Moreover, their conduct has predicted substantial improvements in overall survival in the United States for patients with oncologic disease, suggesting they have contributed meaningfully to this nation's health. These find
Consulte Mais informação »
UK is the leading European tech ecosystem as investors pile inSky's Ian King explains that the UK has established itself as the top European destination for tech investment.
Consulte Mais informação »
“Living Solar Cell” Could Pave The Way For Future Sustainable Energy Tech | OilPrice.comThe researchers say that their method could enable the development of future sustainable, multifunctional green energy technologies.
Consulte Mais informação »
F1 2022 tech review: How Alfa Romeo's short and light C42 helped its revivalAlfa Romeo’s resurgence in 2022 may have gone under the radar but it deserves credit as the team enjoyed its best F1 campaign in a decade 📈 Here’s a technical review of the squad's season and its C42 car ⬇️
Consulte Mais informação »
Shropshire paramedics on picket lines share 'soul-destroying' truth about life in ambulance serviceParamedics held pickets outside ambulance hubs in Shrewsbury and Donnington in Telford on Wednesday, calling for better pay and help to recruit and retain staff as ambulance workers went on strike nationwide.
Consulte Mais informação »